Psychedelics, psychiatry and pharmacokinetics - where are we now?
Alice Caulfield, Elliot Hampsey, Allan H. Young
Expert Opinion on Drug Metabolism & Toxicology August 19, 2025 DOI: 10.1080/17425255.2025.2549987 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Pharmacokinetics Psychedelics |
| Key points | The abstract introduces classical psychedelics as potential treatments for depression, anxiety, and addictions, noting they differ from traditional approaches, but it does not provide a complete finding or argument due to truncation. |
Abstract
1. Classical psychedelics are gaining attention as potential treatments for a range of neuropsychiatric conditions, including depression, anxiety, and addictions [1]. Psychedelics differ from tradi...
Citations in the library
Cited by 2
Cites 19
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
- Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Acta Psychiatrica Scandinavica October 30, 2020
- Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology December 25, 2017
- Psychedelics reopen the social reward learning critical period Nature June 14, 2023
- Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects Neuropsychopharmacology February 25, 2022
and 14 more in the library